Gapping down
In reaction to disappointing earnings/guidance:
- SHLD -10%, CIEN -7.9%, DLTR -7.6%, DG -5.9%, BOX -5.3%, SMTC -0.8%
Other news:
- CLSD -21.6% (after reporting Phase 2 data)
- CRSP -14.1% (CRISPR Therapeutics and Vertex provide update on FDA review of Investigational New Drug Application for CTX001 for the treatment of sickle cell disease - placed on clinical hold)
- VCEL -5.4% (to offer and sell, subject to market and other conditions, 3,750,000 shares of its common stock in an underwritten public offering)
- CHMI -4.8% (prices 2.75 mln common stock offering total expected gross proceeds of $49.6 million)
- CRH -4.2% (will establish a new global Building Products division effective 1 January 2019; initiated a strategic review of its Europe Distribution busines)
- NTLA -3.4% (lower after FDA places CRSP's sickle cell gene therapy on clinical hold)
- EDIT -3.1% (lower after FDA places CRSP's sickle cell gene therapy on clinical hold)
- ABBV -2.8% (releases preliminary results of its modified Dutch auction tender offer)
- VRTX -1.7% (CRISPR Therapeutics and Vertex provide update on FDA review of Investigational New Drug Application for CTX001 for the treatment of sickle cell disease - placed on clinical hold)
Analyst comments:
- MU -2.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- PCAR -1.3% (downgraded to Neutral from Buy at Goldman)
![]()